Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/USP9X_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/USP9X_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/USP9X_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/USP9X_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/USP9X_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/USP9X_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/USP9X_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/USP9X_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/USP9X_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/USP9X_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/USP9X_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000762315 | Prostate | Tumor | circadian rhythm | 75/3246 | 210/18723 | 1.09e-10 | 6.79e-09 | 75 |
GO:001604916 | Prostate | Tumor | cell growth | 137/3246 | 482/18723 | 7.01e-10 | 3.51e-08 | 137 |
GO:007155915 | Prostate | Tumor | response to transforming growth factor beta | 76/3246 | 256/18723 | 6.86e-07 | 1.40e-05 | 76 |
GO:007156015 | Prostate | Tumor | cellular response to transforming growth factor beta stimulus | 72/3246 | 250/18723 | 4.47e-06 | 7.02e-05 | 72 |
GO:000717915 | Prostate | Tumor | transforming growth factor beta receptor signaling pathway | 58/3246 | 198/18723 | 2.11e-05 | 2.72e-04 | 58 |
GO:004275214 | Prostate | Tumor | regulation of circadian rhythm | 39/3246 | 121/18723 | 4.69e-05 | 5.21e-04 | 39 |
GO:005105413 | Prostate | Tumor | positive regulation of DNA metabolic process | 57/3246 | 201/18723 | 6.77e-05 | 7.21e-04 | 57 |
GO:000717815 | Prostate | Tumor | transmembrane receptor protein serine/threonine kinase signaling pathway | 90/3246 | 355/18723 | 7.93e-05 | 8.19e-04 | 90 |
GO:006156413 | Prostate | Tumor | axon development | 113/3246 | 467/18723 | 8.86e-05 | 8.74e-04 | 113 |
GO:005105212 | Prostate | Tumor | regulation of DNA metabolic process | 88/3246 | 359/18723 | 3.23e-04 | 2.59e-03 | 88 |
GO:000740913 | Prostate | Tumor | axonogenesis | 100/3246 | 418/18723 | 3.38e-04 | 2.70e-03 | 100 |
GO:004858814 | Prostate | Tumor | developmental cell growth | 60/3246 | 234/18723 | 8.41e-04 | 5.66e-03 | 60 |
GO:199000015 | Prostate | Tumor | amyloid fibril formation | 14/3246 | 34/18723 | 9.26e-04 | 6.10e-03 | 14 |
GO:006056014 | Prostate | Tumor | developmental growth involved in morphogenesis | 59/3246 | 234/18723 | 1.43e-03 | 8.84e-03 | 59 |
GO:004867514 | Prostate | Tumor | axon extension | 32/3246 | 120/18723 | 6.77e-03 | 3.09e-02 | 32 |
GO:199013814 | Prostate | Tumor | neuron projection extension | 43/3246 | 172/18723 | 6.83e-03 | 3.10e-02 | 43 |
GO:004851119 | Skin | AK | rhythmic process | 67/1910 | 298/18723 | 3.47e-10 | 4.37e-08 | 67 |
GO:006156416 | Skin | AK | axon development | 91/1910 | 467/18723 | 8.60e-10 | 8.63e-08 | 91 |
GO:001604920 | Skin | AK | cell growth | 93/1910 | 482/18723 | 9.55e-10 | 9.42e-08 | 93 |
GO:000762320 | Skin | AK | circadian rhythm | 51/1910 | 210/18723 | 2.80e-09 | 2.40e-07 | 51 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
USP9X | SNV | Missense_Mutation | novel | c.1903N>A | p.Glu635Lys | p.E635K | Q93008 | protein_coding | tolerated(0.3) | benign(0.009) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
USP9X | SNV | Missense_Mutation | novel | c.6115N>A | p.Glu2039Lys | p.E2039K | Q93008 | protein_coding | tolerated(0.05) | benign(0.33) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
USP9X | SNV | Missense_Mutation | | c.1969N>T | p.Arg657Trp | p.R657W | Q93008 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
USP9X | SNV | Missense_Mutation | | c.3418G>C | p.Asp1140His | p.D1140H | Q93008 | protein_coding | deleterious(0.04) | probably_damaging(0.992) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
USP9X | SNV | Missense_Mutation | | c.6586N>G | p.Leu2196Val | p.L2196V | Q93008 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A26J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
USP9X | SNV | Missense_Mutation | | c.1795N>T | p.Arg599Cys | p.R599C | Q93008 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
USP9X | SNV | Missense_Mutation | | c.283N>C | p.Glu95Gln | p.E95Q | Q93008 | protein_coding | deleterious(0.01) | probably_damaging(0.974) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
USP9X | SNV | Missense_Mutation | novel | c.1644G>T | p.Lys548Asn | p.K548N | Q93008 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP9X | SNV | Missense_Mutation | | c.6172C>G | p.His2058Asp | p.H2058D | Q93008 | protein_coding | deleterious(0) | benign(0.347) | TCGA-AN-A0G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
USP9X | SNV | Missense_Mutation | rs371450770 | c.3158N>T | p.Thr1053Met | p.T1053M | Q93008 | protein_coding | deleterious(0.01) | possibly_damaging(0.487) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |